ClinicalTrials.gg

Arthritis, Psoriatic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 601 studies for Arthritis, Psoriatic across more than 10 countries. 128 are recruiting or about to start. 386 of them are mainly about Arthritis, Psoriatic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 659 studies for Arthritis, Psoriatic. How that becomes 599 here

This page counts the studies the registry files under Arthritis, Psoriatic, and those it files under no condition that list Arthritis, Psoriaticthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 659Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −20List Arthritis, Psoriatic as a condition, but the registry did not file them under itMost often written as “Juvenile Psoriatic Arthritis” (9), “Axial Psoriatic Arthritis (axPsA)” (2), and “Arthritis, Psoriatic, Psoriasis” (1). The registry filed them under other conditions only, most often Arthritis, Juvenile (12) and Arthritis (5).
  3. −40Match it another way30 name it in the title, 4 in a keyword, and 6 by a synonym or other text the search reads.
  4. 599The count on this page5 of them list Arthritis, Psoriatic in their own words; the registry filed them under no condition.

Status

Completed
341
Recruiting
87
Active, not recruiting
43
Status unknown
39
Terminated
30
Not yet recruiting
30

Phase

Phase 3
107
Phase 2
67
Phase 4
48
Phase 1
31
Early Phase 1
3

Where

United States
193
Germany
109
Canada
99
Spain
96
United Kingdom
95
Poland
92

Who develops what

Add Arthritis, Psoriatic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 24 programs from 18 companies, 21 with this as their studies’ main aim; 8 with a live phase 3 study; 15 primary completions in the next 12 months. Compare AbbVie, Johnson & Johnson and UCB here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
tofacitinibRecent, repeated
Evidence
  • NCT07406035 · Sino Biopharmaceutical Limited · Phase 2 · live · comparator · “Tofacitinib Citrate Tablet 5 mg” · registered Jan 2026
  • NCT06176508 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · live · comparator · “Tofacitinib 5Mg Tab,Oral” · registered Dec 2023
Pfizer94% of its industry studiesUS: off-patent, 23 generics marketedEU: Pfizer (EMA 2017)22 studies
risankizumabRecent, repeated
Evidence
  • NCT06641089 · MoonLake Immunotherapeutics AG · Phase 3 · live · comparator · “Risankizumab” · registered Oct 2024
  • NCT06624228 · UCB S.A. · Phase 3 · comparator · “Risankizumab” · registered Sep 2024
AbbVie96% of its industry studiesUS: AbbVie (FDA 2019)EU: AbbVie (EMA 2019)22 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
sonelokimab☆ Track3 live phase-3 studies: NCT06641089, NCT06641076, NCT07223138MoonLake Immunotherapeutics AG
icotrokinraApproved: US 2026☆ Track2 live phase-3 studies: NCT06807424, NCT06878404Johnson & Johnson
bimekizumabApproved: US 2023 · EU 2021☆ Track1 live phase-3 study: NCT06506916UCB S.A.
zasocitinib☆ Track4 live phase-3 studies: NCT06671483, NCT07286058, NCT07871721Takeda
picankibart☆ Track1 live phase-3 study: NCT07295509Innovent Biologics, Inc.

The 5 in phase 3 with the nearest primary completion, of 24 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 4 Jan 2027 est.sonelokimab · MoonLake Immunotherapeutics AG · Phase 3 main aimvs risankizumabNCT06641089 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response — primary endpoint: Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) · 600 enrolled
  • Feb 2027 est.CBP-0276 · Clarent Biopharma, Inc. · Phase 2 main aimNCT07706530 Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) — primary endpoint: Change on severity of symptoms at lest 20% at week 24 · 240 enrolled
  • 10 Feb 2027 est.icotrokinra · Johnson & Johnson · Phase 3 main aimNCT06807424 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis — primary endpoint: Proportion of Participants who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16 · 813 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Arthritis, Psoriatic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 7 open · Tyrosine kinase inhibitors (TKIs) 7 open · Antimetabolites 5 open · GLP-1 receptor agonists 2 open · Statins 3

Coming up

53studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 87 Arthritis, Psoriatic studies recruiting now, 52 (60%) set no upper age limit and 26 (30%) stop at 75 or younger. 12 (14%) take children under 18. 4 (5%) are for women only and 1 (1%) for men only; 12 (14%) take healthy volunteers.

Recruiting studies that take each age, of 87
AgeWomenMen
1010 (11%)8 (9%)
1882 (94%)78 (90%)
3083 (95%)79 (91%)
4083 (95%)79 (91%)
5084 (97%)81 (93%)
6581 (93%)78 (90%)
7570 (80%)67 (77%)
8559 (68%)56 (64%)

Across all 601 studies, recruiting or not: 22% stop at 75 or younger and 10% at 65; 9% take children; 3% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Arthritis, Psoriatic studies take

Of 74 phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo5–35 · 15 studies——
Phase 219 mo13–31 · 34 studies——
Phase 328 mo19–42 · 74 studies27 mo18–39 · 68 studies—
Phase 429 mo25–37 · 33 studies——
Interventional, no phase31 mo13–44 · 72 studies—31 mo16–43 · 67 studies
Observational47 mo28–82 · 128 studies47 mo32–63 · 52 studies53 mo20–… · 76 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 601. Browse all 601 → or search them.